Skip to content

Study of the Expression of Heat Shock Proteins in Populations of B Lymphocytes in Human Tonsils

Single-centre Study of the Expression of Heat Shock Proteins in the Lymphocytes From the Tonsils of Patients With Various Diseases Requiring Tonsillectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02859090
Acronym
HOTLYMPHO
Enrollment
5
Registered
2016-08-08
Start date
2014-08-26
Completion date
2014-11-20
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tonsillectomy

Brief summary

It has recently been shown that various HSPs are strongly expressed in B lymphomas. Indeed, HSP90 stabilizes the protein Bcl-6 in diffuse large-cell B lymphomas. Pharmacological inhibition of HSP90 in vitro induced apoptosis in lymphoma cells (Cerchietti et al. Nat. Medicine, 2009, 1369-1376). In addition, HSP110 is strongly expressed in non-Hodgkin lymphomas, and targeting this HSP at the cell surface using specific antibodies could constitute a future therapy (Zappasodi et al. Blood, 2011, 4421-4430). Despite the importance of these proteins in the development of lymphomas, their expression and their role in the activation of normal B lymphocytes and the normal development of germinal centres is not known. The expression of Heat shock proteins should vary among the different B lymphocyte populations present in the tonsils (naïve B cells, memory B cells, germinal centre B cells). The aim of this study is to establish an expression profile for heat shock proteins in populations of B lymphocytes in human tonsils

Interventions

PROCEDUREtonsillectomy
BIOLOGICALblood sample

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Persons who have provided oral consent * Tonsillectomy in children or adults

Exclusion criteria

* Persons without national health insurance cover * Adults under guardianship * Pregnant or breast-feeding women * Persons with positive HIV or HCV serology

Design outcomes

Primary

MeasureTime frame
expression of heat shock proteinsDay one

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026